In contrast, the detection of a TP53 variant in a small fraction of NGS reads from blood DNA does not always correspond to a mosaic alteration [22–25] and molecular geneticists should be aware of two pitfalls: the first corresponds to circulating tumour DNA, commonly observed in patients with metastatic cancers. The gene discussed is TP53; the disease is neoplasm.